UpcomingPDUFA target action date

Oxnimbi (AD109)

Apnimed (APMD)

Marketer take

An oral OSA option would reach sleep specialists and primary care in a market built around CPAP and devices, with tirzepatide already approved for OSA in adults with obesity.

Sponsor company
Apnimed (APMD)
Indication
Obstructive sleep apnea
Therapeutic area
Sleep, Pulmonology
Event
PDUFA target action date
Date
Feb 28, 2027
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move